Акушерство и Гинекология Санкт-Петербурга. 2017; : 39-44
Антифосфолипидный синдром в акушерской практике
Аннотация
Антифосфолипидный синдром (АФС) - это аутоиммунное заболевание, характеризующееся развитием сосудистых тромбозов (артериальных и венозных) и/или акушерской патологии при наличии постоянно циркулирующих антифосфолипидных антител (антител к кардиолипину), волчаночного антикоагулянта и антител к Р2-гликопротеину-1, определенных у пациента два и более раз с интервалом не менее 12 недель [1]. Несмотря на то, что не все патогенетические механизмы достаточно изучены и исследования в этой области активно продолжаются, доказано и не вызывает сомнений ученых, что антифосфолипидные антитела многосторонне влияют на процессы формирования и развития трофобласта с момента установления маточно-плацентарного кровотока.
Список литературы
1. Сидельникова В.М. Подготовка и ведение беременности у женщин с привычным невынашиванием. Методические пособия и клинические протоколы. 3-е издание. Москва: МЕДпресс-информ. 2013.
2. Макацария А.Д. Тромбогеморрагические осложнения в акушерско-гинекологической практике. М.: МИА. 2011.
3. Макацария А.Д., Бицадзе В.О., ХизроеваД.Х., с соавт. Патогенетическое значение антифосфолипидных антител. Практическая медицина. 2012; 5 (60): 9-21.
4. Радзинский В. Неразвивающаяся беременность. 2-е изд., перераб. и доп. М.: «ГЭОТАР-Медиа». 2016.
5. ХизроеваД.Х., Машкова Т.М. Вспомогательные репродуктивные технологии и антифософлипидный синдром. Акушерство, гинекология и репродукция. 2014; 8 (1): 26-30.
6. Чепанов С.В., Соколов Д.И., Шляхтенко Т.Н. с соавт. Экспериментальное обоснование эндотелиопротективного эффекта иммуноглобулинов для внутривенного введения при акушерской патологии. Акушерство и гинекология. 2016; 5: 82-89.
7. Шаповалова Е.А. Привычное невынашивание беременности при наличии циркулирующих антифосфолипидных антител (клиника, диагностика, лечение): Автореф. дисс. ... канд. мед. наук. Санкт-Петербург. 2001.
8. Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа. 2010.
9. Branch D.W., Khamashta M.A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet. Gynecol. 2003; 101 (6): 1333-1344.
10. Branch D.W., Silver R.M., Porter T.F. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus. 2010; 19 (4): 446-452. doi: 10.1177/0961203310361490.
11. Cervera R., Khamashta M.A., Shoenfeld Y. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2009; 68 (9): 1428-1432. http://dx.doi.org/10.1136/ard.2008.093179
12. Cooper G.S., Bynum M.L.K., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 2009; 33 (3-4): 197-207. doi: 10.1016/j.jaut.2009.09.008.
13. CooperGS., Stroehla B.C. The epidemiology ofautoimmune diseases. Autoimmun. Rev. 2003; 2 (3): 119-125.
14. Costedoat-Chalumeau N., Guettrot-ImbertG., Leguern V. etal. Pregnancy and antiphospholipid syndrome. La Rev. Med. interne. 2012. 33 (4): 209-216. doi: 10.1016/j.revmed.2012.01.003 (French).
15. D'Ippolito S., Marana R., Nicuoloi F.D. et al. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun. Rev. 2014; 13 (9): 901-908. doi: 10.1016/j.autrev.2014.05.004.
16. Ernest J., Marshburn P., Kutteh W. Obstetric Antiphospholipid Syndrome: An Update on Pathophysiology and Management. Semin. Reprod. Med. 2011; 29 (6): 522-539. doi: 10.1055/s-0031-1293206.
17. Khamashta M., Taraborelli M., Sciascia S. et al. Antiphospholipid syndrome. Best Pract. Res. Clin. Rheumatol. 2016; 30 (1): 133-148. doi: 10.1016/j.berh.2016.04.002.
18. Kim E., DoT., PeacockK., TakundwaPT. Recommended therapeutic INR range for patients with antiphospholipid syndrome on warfarin anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for reducing risk of recurrent thromboembolic events? Cureus. 2016; 8(9):e765. doi: 10.7759/cureus.765.
19. Kutteh W.H.,RoteN.S.,SilverR. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am. J. Reprod. Immunol. 1999; 41 (2): 133-152. doi: 10.1111/j.1600-0897.1999.tb00087.x.
20. Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
21. Pengo V., Ruffatti A., Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 2010; 8 (2): 237-242. doi: 10.1111/j.1538-7836.2009.03674.x.
22. Simone N. Di, Castellani R., Caliandro D. et al. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil. Steril. 2002; 77 (4): 805-811. doi: https://doi.org/10.1016/S0015-0282(01)03258-7.
23. Simone N. Di, Nicuolo F. Di, D'Ippolito S. et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol. Reprod. 2010; 83 (2): 212219. https://doi.org/10.1095/biolreprod.110.083410.
24. Viall C.A., Chamley L.W. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun. Rev. 2015; 14 (5): 446-471. doi: 10.1016/j.autrev.2015.01.008.
25. Shi H., Zheng H., Yin Y.F., Hu Q.Y., Teng J.L., Sun Y. et al. Antiphosphatidylserine/ prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors ofvenous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2017; pii: /j/cclm.ahead-of-print/cclm-2017-0502/cclm-2017-0502.xml. doi: 10.1515/cclm-2017-0502.
26. Kaneko K., Mishima S., Goto M., Mitsui M., Tanigaki S., Oku K. et al. Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy. Modern Rheumatology. 2017; 1-6. doi: 10.1080/14397595.2017.1386845.
27. Lockshin M.D., Druzin M.L., Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am. J. Obstet. Gynecol. 1989; 160(2): 439-443. doi: https://doi.org/10.1016/0002-9378(89)90468-7.
Obstetrics and Gynaecology of Saint-Petersburg. 2017; : 39-44
Antiphospholipid syndrome in obstetrical practice
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the development of vascular thrombosis (arterial and venous) and / or obstetric pathology in the presence of constantly circulating antiphospholipid antibodies (antibodies to cardiolipin), lupus anticoagulant and antibodies to p2-glycoprotein-1, determined in the patient two or more times with an interval of at least 12 weeks [1]. Despite the fact that not all pathogenetic mechanisms have been sufficiently studied and studies in this field are actively continuing, it is proved and there is no doubt among scientists that antiphospholipid antibodies affect the formation and development of trophoblast from the moment of establishment of uteroplacental blood flow.
References
1. Sidel'nikova V.M. Podgotovka i vedenie beremennosti u zhenshchin s privychnym nevynashivaniem. Metodicheskie posobiya i klinicheskie protokoly. 3-e izdanie. Moskva: MEDpress-inform. 2013.
2. Makatsariya A.D. Trombogemorragicheskie oslozhneniya v akushersko-ginekologicheskoi praktike. M.: MIA. 2011.
3. Makatsariya A.D., Bitsadze V.O., KhizroevaD.Kh., s soavt. Patogeneticheskoe znachenie antifosfolipidnykh antitel. Prakticheskaya meditsina. 2012; 5 (60): 9-21.
4. Radzinskii V. Nerazvivayushchayasya beremennost'. 2-e izd., pererab. i dop. M.: «GEOTAR-Media». 2016.
5. KhizroevaD.Kh., Mashkova T.M. Vspomogatel'nye reproduktivnye tekhnologii i antifosoflipidnyi sindrom. Akusherstvo, ginekologiya i reproduktsiya. 2014; 8 (1): 26-30.
6. Chepanov S.V., Sokolov D.I., Shlyakhtenko T.N. s soavt. Eksperimental'noe obosnovanie endotelioprotektivnogo effekta immunoglobulinov dlya vnutrivennogo vvedeniya pri akusherskoi patologii. Akusherstvo i ginekologiya. 2016; 5: 82-89.
7. Shapovalova E.A. Privychnoe nevynashivanie beremennosti pri nalichii tsirkuliruyushchikh antifosfolipidnykh antitel (klinika, diagnostika, lechenie): Avtoref. diss. ... kand. med. nauk. Sankt-Peterburg. 2001.
8. Yarilin A.A. Immunologiya. M.: GEOTAR-Media. 2010.
9. Branch D.W., Khamashta M.A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet. Gynecol. 2003; 101 (6): 1333-1344.
10. Branch D.W., Silver R.M., Porter T.F. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus. 2010; 19 (4): 446-452. doi: 10.1177/0961203310361490.
11. Cervera R., Khamashta M.A., Shoenfeld Y. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2009; 68 (9): 1428-1432. http://dx.doi.org/10.1136/ard.2008.093179
12. Cooper G.S., Bynum M.L.K., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 2009; 33 (3-4): 197-207. doi: 10.1016/j.jaut.2009.09.008.
13. CooperGS., Stroehla B.C. The epidemiology ofautoimmune diseases. Autoimmun. Rev. 2003; 2 (3): 119-125.
14. Costedoat-Chalumeau N., Guettrot-ImbertG., Leguern V. etal. Pregnancy and antiphospholipid syndrome. La Rev. Med. interne. 2012. 33 (4): 209-216. doi: 10.1016/j.revmed.2012.01.003 (French).
15. D'Ippolito S., Marana R., Nicuoloi F.D. et al. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun. Rev. 2014; 13 (9): 901-908. doi: 10.1016/j.autrev.2014.05.004.
16. Ernest J., Marshburn P., Kutteh W. Obstetric Antiphospholipid Syndrome: An Update on Pathophysiology and Management. Semin. Reprod. Med. 2011; 29 (6): 522-539. doi: 10.1055/s-0031-1293206.
17. Khamashta M., Taraborelli M., Sciascia S. et al. Antiphospholipid syndrome. Best Pract. Res. Clin. Rheumatol. 2016; 30 (1): 133-148. doi: 10.1016/j.berh.2016.04.002.
18. Kim E., DoT., PeacockK., TakundwaPT. Recommended therapeutic INR range for patients with antiphospholipid syndrome on warfarin anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for reducing risk of recurrent thromboembolic events? Cureus. 2016; 8(9):e765. doi: 10.7759/cureus.765.
19. Kutteh W.H.,RoteN.S.,SilverR. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am. J. Reprod. Immunol. 1999; 41 (2): 133-152. doi: 10.1111/j.1600-0897.1999.tb00087.x.
20. Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
21. Pengo V., Ruffatti A., Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 2010; 8 (2): 237-242. doi: 10.1111/j.1538-7836.2009.03674.x.
22. Simone N. Di, Castellani R., Caliandro D. et al. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil. Steril. 2002; 77 (4): 805-811. doi: https://doi.org/10.1016/S0015-0282(01)03258-7.
23. Simone N. Di, Nicuolo F. Di, D'Ippolito S. et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol. Reprod. 2010; 83 (2): 212219. https://doi.org/10.1095/biolreprod.110.083410.
24. Viall C.A., Chamley L.W. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun. Rev. 2015; 14 (5): 446-471. doi: 10.1016/j.autrev.2015.01.008.
25. Shi H., Zheng H., Yin Y.F., Hu Q.Y., Teng J.L., Sun Y. et al. Antiphosphatidylserine/ prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors ofvenous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2017; pii: /j/cclm.ahead-of-print/cclm-2017-0502/cclm-2017-0502.xml. doi: 10.1515/cclm-2017-0502.
26. Kaneko K., Mishima S., Goto M., Mitsui M., Tanigaki S., Oku K. et al. Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy. Modern Rheumatology. 2017; 1-6. doi: 10.1080/14397595.2017.1386845.
27. Lockshin M.D., Druzin M.L., Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am. J. Obstet. Gynecol. 1989; 160(2): 439-443. doi: https://doi.org/10.1016/0002-9378(89)90468-7.
